Personalized medicine in advanced urothelial cancer: When to treat, how to treat and who to treat

Journal of the Canadian Urological Association

Volumn 3, Issue 6 SUPPL. 4, 2009, Pages

  Ehdaie, Behfar ^a   Smith, Steven C ^a   Theodorescu, Dan ^a,b  

^a Department of Urology ^*  (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 75849160171     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
3. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54: 784-8.
4. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005; 5: 713-25.
5. Holmang S, Hedelin H, Anderstrom C, et al. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995; 153: 1823-6.; discussion 1826-7.
6. Prout GR, Marshall VF. The prognosis with untreated bladder tumors. Cancer 1956; 9: 551-8.
7. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-75.
8. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-66.
9. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42: 50-4.
10. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-8.
11. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15: 2564-9.
12. Ennis RD, Petrylak DP, Singh P, et al. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer. J Urol 2000; 163: 1413-8.
13. Slaton JW, Swanson DA, Grossman HB, et al. A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 1999; 162(3Pt1): 710-4.
14. Bassi P, Ferrante GD, Piazza N, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 1999; 161: 1494-7.
15. Lotan Y, Gupta A, Shariat SF, et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 2005; 23: 6533-9.
16. Frazier HA, Robertson JE, Dodge RK, et al. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1993; 71: 3993-4001.
17. Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006; 24: 3967-72.
18. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173-81.
19. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 1259-64.
20. Esrig D, Spruck CH 3rd, Nichols PW, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143: 1389-97.
21. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993; 85: 53-9.
22. Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004; 22: 1014-24.
23. Tokunaga H, Shariat SF, Green AE, et al. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys 2001; 51: 16-22.
24. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004; 22: 1007-13.
25. Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998; 58: 1090-4.
26. Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998; 90: 1072-9.
27. Shariat SF, Ashfaq R, Sagalowsky AI, et al. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 2006; 37: 1568-76.
28. Shariat SF, Ashfaq R, Sagalowsky AI, et al. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007; 177: 481-7; discussion 487.
29. Karam JA, Lotan Y, Karakiewicz PI, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007; 8: 128-36.
30. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008; 112: 315-25.
31. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-10.
32. Malats N, Bustos A, Nascimento CM, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005; 6: 678-86.
33. Mitra AP, Birkhahn M, Cote RJ. p53 and retinoblastoma pathways in bladder cancer. World J Urol 2007; 25: 563-71.
34. McKnight JJ, Gray SB, O'Kane HF, et al. Apoptosis and chemotherapy for bladder cancer. J Urol 2005; 173: 683-90.
35. Kong G, Shin KY, Oh YH, et al. Bcl-2 and p53 expressions in invasive bladder cancers. Acta Oncol 1998; 37: 715-20.
36. Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001; 285: 324-8.
37. Shariat SF, Ashfaq R, Karakiewicz PI, et al. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007; 109: 1106-13.
38. Jebar AH, Hurst CD, Tomlinson DC, et al. Jebar AH, et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005; 24: 5218-25.
39. Wulfing C, Machiels J, Richel D, et al. A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma of the urothelial tract. Proc Am Soc Clin Oncol 2005; 23(16S): 401s.
40. Theodorescu D, Sapinoso LM, Conaway MR, et al. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 2004; 10: 3800-6.
41. Titus B, Frierson HF Jr, Conaway M, et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 2005; 65: 7320-7.
42. Smith SC, Oxford G, Wu Z, et al. The Metastasis-Associated Gene CD24 Is Regulated by Ral GTPase and Is a Mediator of Cell Proliferation and Survival in Human Cancer. Cancer Res 2006; 66: 1917-22.
43. Smith S, Overdevest J, McRoberts K, et al. Monoclonal antibody therapy targeting CD24+ bladder cancer cells in vivo. AACR Meeting Abstracts 2008 2008; 4593.
44. Dyrskjøt L, Thykjaer T, Kruhøffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003; 33: 90-6.
45. Sanchez-Carbayo M, Socci ND, Lozano J, et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006; 24: 778-89.
46. Dyrskjøt L, Zieger K, Kruhøffer M, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 2005; 11: 4029-36.
47. Dyrskjøt L, Zieger K, Real FX, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 2007; 13: 3545-51.
48. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005; 11: 2625-36.
49. Takata R, Katagiri T, Kanehira M, et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci 2007; 98: 113-7.
50. Als AB, Dyrskjøt L, von der Maase H, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007; 13(15Pt1): 4407-14.
51. Havaleshko DM, Cho H, Conaway M, et al. Prediction of drug combination chemosensitivity in human bladder cancer. Mol Cancer Ther 2007; 6: 578-86.
52. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 2007; 104: 13086-91.
53. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006; 6: 813-23.
54. Pusztai L. Current status of prognostic profiling in breast cancer. Oncologist 2008; 13: 350-60.